{
  "ticker": "RAPT",
  "company_name": "RAPT Therapeutics, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT04894994",
      "title": "FLX475 in Combination With Ipilimumab in Advanced Melanoma",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Advanced Melanoma",
      "start_date": "2021-09-03",
      "completion_date": "2022-09-13",
      "enrollment": 0,
      "sponsor": "RAPT Therapeutics, Inc."
    },
    {
      "nct_id": "NCT05399368",
      "title": "An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Atopic Dermatitis",
      "start_date": "2022-06-07",
      "completion_date": "2024-05-24",
      "enrollment": 0,
      "sponsor": "RAPT Therapeutics, Inc."
    },
    {
      "nct_id": "NCT02335814",
      "title": "First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Acute Myeloid Leukemia",
      "start_date": "2015-04-08",
      "completion_date": "2017-05-03",
      "enrollment": 0,
      "sponsor": "RAPT Therapeutics, Inc."
    },
    {
      "nct_id": "NCT06087978",
      "title": "Study of RPT193 in Healthy Adult Male Subjects",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Male Subjects",
      "start_date": "2023-07-05",
      "completion_date": "2023-10-12",
      "enrollment": 0,
      "sponsor": "RAPT Therapeutics, Inc."
    },
    {
      "nct_id": "NCT07220811",
      "title": "Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Ig-E Mediated Food Allergy",
      "start_date": "2025-10-22",
      "completion_date": "2028-01",
      "enrollment": 0,
      "sponsor": "RAPT Therapeutics, Inc."
    },
    {
      "nct_id": "NCT04271514",
      "title": "A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Atopic Dermatitis",
      "start_date": "2019-08-12",
      "completion_date": "2021-04-26",
      "enrollment": 0,
      "sponsor": "RAPT Therapeutics, Inc."
    },
    {
      "nct_id": "NCT05935332",
      "title": "Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Asthma",
      "start_date": "2023-07-05",
      "completion_date": "2024-06-21",
      "enrollment": 0,
      "sponsor": "RAPT Therapeutics, Inc."
    },
    {
      "nct_id": "NCT03674567",
      "title": "Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Advanced Cancer",
      "start_date": "2018-09-25",
      "completion_date": "2024-12-31",
      "enrollment": 0,
      "sponsor": "RAPT Therapeutics, Inc."
    }
  ],
  "summary": {
    "total_trials": 8,
    "by_phase": {
      "PHASE2": 4,
      "PHASE1": 3,
      "PHASE1, PHASE2": 1
    },
    "by_status": {
      "TERMINATED": 4,
      "COMPLETED": 3,
      "RECRUITING": 1
    },
    "active_trials": 1,
    "completed_trials": 3,
    "conditions": [
      "Acute Myeloid Leukemia",
      "Advanced Cancer",
      "Advanced Melanoma",
      "Asthma",
      "Atopic Dermatitis",
      "Healthy Male Subjects",
      "Ig-E Mediated Food Allergy"
    ],
    "lead_stage": "phase_2"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:21:20.107012",
    "search_query": "RAPT Therapeutics, Inc.",
    "url": "https://clinicaltrials.gov/search?term=RAPT+Therapeutics,+Inc."
  }
}